SELLAS Life Sciences Announces The Appointment Of Dr. Linghua Wang, MD, PhD, To Its Scientific Advisory Board

Sellas Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company focused on developing novel therapies across a broad range of cancer indications, has announced the appointment of Dr. Linghua Wang to its Scientific Advisory Board (SAB). Dr. Wang brings extensive expertise in cancer genomics and translational science and joins the SAB following the recent additions of Dr. Philip C. Amrein and Dr. Alex Kentsis.

Dr. Wang is a tenured Associate Professor in the Department of Genomic Medicine at MD Anderson Cancer Center, where she leads the Computational Biology Laboratory. She also holds a dual appointment as an Associate Member of The James P. Allison Institute and serves as Co-Lead of Focus Area 2, which focuses on single-cell analytics and spatial multi-omics, at the Institute for Data Science in Oncology. In addition, she is a faculty member in the Quantitative Sciences and Immunology PhD Programs at the UTHealth Houston Graduate School of Biomedical Sciences.

Her academic and research background includes a PhD in Cancer Genomics from the University of Tokyo and postdoctoral training at Baylor College of Medicine, where she later became a faculty member. She joined MD Anderson in 2017. Trained in clinical medicine and cancer biology, Dr. Wang's research concentrates on understanding the complexity of tumor ecosystems. Her work explores cellular and molecular heterogeneity, tumor plasticity, and interactions within the tumor microenvironment that influence disease progression and treatment response.

Dragan Cicic, MD, Senior Vice President, Chief Development Officer of SELLAS, stated, “We are thrilled to welcome Dr. Wang to our Scientific Advisory Board. Her decades of experience in cancer immunogenomics and computational biology are directly aligned with our focus on translational research, artificial intelligence utilization around genomics, proteomics as well as transcriptomics, and precision medicine. With the recent additions of Drs. Amrein and Kentsis, we are building a uniquely experienced and visionary team that will help guide our scientific and clinical strategy during this critical phase of growth. Their collective insights will be invaluable as we approach key clinical milestones expected for both of our assets later this year.”

Dr. Wang’s laboratory integrates advanced technologies such as single-cell and spatial omics, molecular imaging, artificial intelligence-based pathology, and bioinformatics to identify novel therapeutic targets and improve predictive models in oncology. Her goal is to support the development of precision medicine strategies that transform cancer detection, classification, and treatment. 

She has received multiple research grants from the NIH and NCI and has authored over 100 publications in leading scientific journals. Dr. Wang is internationally recognized for her collaborative work, which spans both national and global partnerships in cancer research. Her appointment is expected to significantly enhance the scientific direction of Sellas’ oncology programs.